Ligand Pharma (LGND) PT Raised to $345 at RBC Capital
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $283.49 -0.43%
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $345.00 (from $340.00) while maintaining a Outperform rating.
You May Also Be Interested In
- JPMorgan Downgrades Mapletree Logistics Trust (MLT:SP) (MAPGF) to Neutral
- Bank of Hangzhou Co Ltd (600926:CH) PT Raised to RMB17.30 at JPMorgan
- Lasertec Corp. (6920:JP) (LSRCF) PT Raised to JPY41,800 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
